Abstracts

A RANDOMIZED CONTROLLED TRIAL OF CAMOSTAT IN OUTPATIENTS WITH COVID-19

Camostat, an oral protease inhibitor, blocks entry and replication of SARS-CoV-1 and SARS-CoV-2 in vitro. It is approved for therapy of recurrent pancreatitis in several countries. Camostat has an excellent safety profile and repurposing for COVID-19 treatment was proposed. We conducted a phase 2 randomized, placebo-controlled trial of camostat in adult outpatients with confirmed COVID-19…

LONG-ACTING DORAVIRINE FOR TREATMENT AND PREVENTION OF VAGINAL HIV TRANSMISSION

Non-adherence to HIV treatment is an important health care problem with subsequent development of drug resistance and disease progression. Doravirine (DOR) is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with high activity against both wild-type virus (IC50 5.2ng/ml) and the most prevalent NNRTI-resistant HIV variants. We developed injectable long-acting (LA) formulations of DOR that form…

EVG/COBI/FTC/TAF TABLETS DISSOLVED IN TAP WATER NEAR BIOEQUIVALENT WITH WHOLE TABLETS

Medication adherence can be challenging for persons with pill aversion, dysphagia, odynophagia, or problems swallowing tablets. To provide an alternate to whole Genvoya tablets, we investigated the bioequivalence of a dissolved tablet when compared to a whole tablet of Genvoya, a fixed-dose combination Elvitegravir (EVG)/Cobicistat (COBI)/Emtricitabine (FTC)/Tenofovir (TFV) Alafenamide Fumarate (TAF). A within-subject, fixed-order, two-period,…

TRANSFORMATION OF DOLUTEGRAVIR INTO A YEAR-LONG PARENTERAL PRODRUG FORMULATION

Antiretroviral therapy (ART) requires lifelong daily dosing to attain durable viral suppression. However, regimen adherence dictates effective long-term clinical response by precluding viral rebound. To improve ART effectiveness and ensure adherence, long-acting injectables of cabotegravir and rilpivirine (CAB and RPV LA) were developed. Nonetheless, limitations include high injection volumes, limited drug tissue distribution, and frequent…

IMPACT OF HYALURONIDASE ON LONG-ACTING DRUG RELEASE PHARMACOKINETICS IN MURINE MODELS

Developing long-acting injectable formulations (LAI) of drugs for prevention/treatment of HIV and tuberculosis is of great interest. A key issue in LAI development is the injection volume needed to sustain drug exposure. Co-administration of the extracellular matrix-degrading enzyme hyaluronidase (HYL) can increase maximum tolerable injection volume and is untested for this benefit for any LAI…

PHARMACOGENETICS OF DOLUTEGRAVIR PLASMA EXPOSURE AMONG SOUTH AFRICANS LIVING WITH HIV

Dolutegravir (DTG) is a component of preferred first-line antiretroviral therapy (ART) regimens. DTG is metabolized primarily by UGT1A1, and UGT1A1 variants affect DTG plasma exposure. There are limited data on DTG pharmacogenetics in Africa. We characterized genetic associations with estimated plasma DTG area under the concentration-time curve (AUC) among African participants who initiated DTG-containing ART…